Results 261 to 270 of about 73,942 (286)

Targeting Mast Cells in Endometriosis with Janus Kinase 3 Inhibitor, JANEX‐1

American Journal of Reproductive Immunology, 2007
Endometriosis (EMS) is a chronic inflammatory disease of multifactorial etiology characterized by implantation and growth of endometrial glands and stroma outside the uterine cavity. EMS is a significant public health issue as it affects 15–20% of women in their reproductive age.
Osmond J, D'Cruz, Fatih M, Uckun
openaire   +2 more sources

Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma

Science Translational Medicine, 2018
Inhalation of a Janus kinase 1 inhibitor suppressed lung inflammation without systemic side effects in rodent models of asthma.
Hart S. Dengler, Xiumin Wu, Ivan Peng, Cornelia H. Rinderknecht, Youngsu Kwon, Eric Suto, Pawan Bir Kohli, Marya Liimatta, Kathy Barrett, Julia Lloyd, Gary Cain, Mike Briggs, Stephanie Addo, Gary Salmon, Savita Ubhayakar, Gauri Deshmukh, Sheerin K. Shahidi-Latham, Cristine M. Quiason-Huynh, Janet Jackman, John Liu, Nicholas C. Ray, Simon C. Goodacre, Adam Johnson, Brent S. McKenzie, Wyne P. Lee, Mark Zak, Jane R. Kenny, Nico Ghilardi   +27 more
openaire   +2 more sources

Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis

Leukemia & Lymphoma, 2015
Hyperactive Janus associated kinase-signal transducers and activators of transcription (JAK-STAT) signaling has been shown to be integral to the pathogenesis of myelofibrosis (MF) regardless of the driver mutational status (JAK2V617F, JAK2 exon 12, MPL515L/K, CALR). Targeting of the JAK-STAT pathway has been the intense focus of therapeutic development
openaire   +2 more sources

Itaconate inhibits alternative activation of macrophages by targeting Janus Kinase 1

The Journal of Immunology, 2019
Abstract In innate immune cells, TCA cycle components are not simply inert metabolites, but are key signaling molecules that can modulate inflammatory responses. Itaconate, an immunometabolite made by the enzyme aconitase decarboxylase (encoded by the gene Irg1), is highly upregulated in classically activated M1 macrophages and regulates
Marah C Runtsch, Luke O’Neill
openaire   +1 more source

Reversible effects on female rat fertility with abrocitinib, a Janus kinase 1 inhibitor

Birth Defects Research
AbstractBackgroundAbrocitinib is a Janus kinase (JAK) 1 selective inhibitor approved for the treatment of atopic dermatitis. Female reproductive tissues were unaffected in general toxicity studies, but an initial female rat fertility study resulted in adverse effects at all doses evaluated.
Christopher J. Bowman, Sarah N. Campion, Natasha R. Catlin, William S. Nowland, Christine M. Stethem, Zaher A. Radi, Gregg D. Cappon   +6 more
openaire   +2 more sources

The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus

Journal of the European Academy of Dermatology and Venereology, 2023
Farzan Solimani, Alberto Mesas‐Fernández, Amrei Dilling, Alexander Nast, Franz J. Hilke, Franziska C. Ghoreschi, Margitta Worm, Kamran Ghoreschi, Katharina Meier   +8 more
openaire   +2 more sources

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus

Journal of Inflammation Research, 2023
Rongxiu Huo, Xinxiang Huang, Jinying Lin   +2 more
exaly  

Structural basis of Janus kinase trans-activation

Cell Reports, 2023
Nathanael A Caveney, Robert A Saxton, Deepa Waghray   +2 more
exaly  

Efficacy of Janus kinase 1 and 2 inhibitor baricitinib in multirefractory cutaneous dermatomyositis

Annales de Dermatologie et de Vénéréologie, 2023
S. Karaa, C. Cassius, M. Jachiet, T. Mahevas, E. Charvet, O. Benveniste, J.-D. Bouaziz   +6 more
openaire   +2 more sources

Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis

Mayo Clinic Proceedings, 2021
Jawad Bilal, Irbaz bin Riaz, Syed Arsalan Ahmed Naqvi   +2 more
exaly